Year Founded
2007
Ownership
Private
Employees
~50
Stage
Commercial
Modalities
Small molecule

H.A.C. Pharma General Information

Independent French pharmaceutical company focused on maintaining availability of essential and proven medicines. Recently acquired European and UK rights to TARGRETIN (bexarotene) from Eisai and TROPHICREME (estriol) from Sanofi.

Contact Information

Website
Primary Industry
[ "Pharma" ]
Corporate Office
Caen,
France

Drug Pipeline

bexarotene
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to H.A.C. Pharma's pipeline data

Book a demo

Key Partnerships

Eisai, Sanofi, Iroko Pharmaceutical, Aspen, AGEPS, Medice

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

H.A.C. Pharma Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view H.A.C. Pharma's complete valuation and funding history, request access »